Inhibrx Biosciences, Inc.
INBX
$29.59
$0.4851.67%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -110.02% | 714.34% | 799.19% | -- | -- |
| Total Depreciation and Amortization | 93.67% | 107.01% | 91.86% | -- | -- |
| Total Amortization of Deferred Charges | -74.53% | -77.92% | -57.85% | -- | -- |
| Total Other Non-Cash Items | 100.67% | -6,949.67% | -7,383.32% | -- | -- |
| Change in Net Operating Assets | -88.53% | 215.18% | 239.14% | -- | -- |
| Cash from Operations | 39.58% | 27.10% | -0.57% | -- | -- |
| Capital Expenditure | 95.69% | 73.65% | 43.46% | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 95.69% | 73.65% | 43.46% | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -100.00% | -86.33% | -64.57% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 64.79% | 99.54% | -- | -- | -- |
| Cash from Financing | -63.35% | -37.87% | -64.51% | -- | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -217.24% | -68.19% | -3,187.66% | -- | -- |